Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 690
- Registration Number
- NCT00288951
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2012-03-05
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 87
- Registration Number
- NCT00287521
- Locations
- ๐บ๐ธ
United States Investigative Sites in Texas and Other States, Fort Worth, Texas, United States
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients
- First Posted Date
- 2003-10-06
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 118
- Registration Number
- NCT00069706
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-10-06
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT00069719
- Locations
- ๐บ๐ธ
Alcon Clinical Trial Sites, Multiple Locations Throughout the US Sponsored by Alcon of, Texas, United States
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2003-08-01
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 111
- Registration Number
- NCT00065728
- Locations
- ๐บ๐ธ
Belgium,France,Germany,Hungary,Italy,Netherlands,Poland,Spain,Sweden,UK, Central Contact Ft. Worth, Texas, United States
Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension
Phase 4
Completed
- Conditions
- First Posted Date
- 2003-05-30
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT00061503
- Locations
- ๐บ๐ธ
Alcon Call Center, Call for Details, Nebraska, United States
Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-05-30
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 105
- Registration Number
- NCT00061542
- Locations
- ๐บ๐ธ
Alcon Call Center, Fort Worth, Texas, United States
Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-05-30
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 78
- Registration Number
- NCT00061516
A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-05-30
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT00061529
- Locations
- ๐บ๐ธ
Alcon Call Center, Fort Worth, Texas, United States
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2012-11-29
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT00058994
- Locations
- ๐บ๐ธ
South America, Fort Worth, Texas, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath